Analyst Rating Update on Sangamo BioSciences (SGMO)

Sangamo BioSciences (SGMO) : 7 analysts are covering Sangamo BioSciences (SGMO) and their average rating on the stock is 1, which is read as a Strong Buy. 7 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.

Sangamo BioSciences (SGMO) : Average target price received by Sangamo BioSciences (SGMO) is $18.4 with an expected standard deviation of $6.58. The most aggressive target on the stock is $30, whereas the most downbeat target is $14. 5 financial analysts are currently covering the stock.

For this week, the average consensus of the company shares are rated as a Strong Buy.


Sangamo BioSciences (NASDAQ:SGMO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.52 and $6.49 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.91. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.84, notching a gain of 4.11% for the day. The total traded volume was 904,545 . The stock had closed at $6.57 on the previous day.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *